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ABSTRACT:  
Driven by the continuous improvement of the accuracy of cross-sectional imaging, image-
guided minimally invasive local ablative therapies have received incremental interest over the 
past years. This study systematically reviews the currently available literature on [18F]FDG 
PET/CT to monitor the efficacy of these local ablative therapies. By including all local ablative 
treatment modalities, tumor types and organ sites, we provide a comprehensive overview of 
current status, identify general patterns across studies and provide recommendations for 
future studies and clinical practice. The QUADAS criteria are used to assess the quality of 
reported diagnostic accuracy of the retrieved studies.  
Data in literature suggest that [18F]FDG PET/CT is a highly accurate tool to assess technical 
success of local treatment, to identify residual or recurrent tumor early after intervention and 
to provide prognostic and predictive information. However, prospective interventional studies 
based on [18F]FDG PET/CT findings of disease activity are mandatory to develop uniform 
and quantitative criteria for PET evaluation. Moreover, the optimal timing of [18F]FDG 
PET/CT after treatment may vary on the localization of disease, allowing (very) early imaging 
in solid organs as the liver, while post-treatment inflammation is a challenge in the first 3 
months after therapy in the lung parenchyma.  
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INTRODUCTION: 
Driven by the continuous improvement of the accuracy of cross-sectional imaging for 
oncological applications, image-guided minimally invasive local ablative therapies have 
received incremental interest for several reasons. More sensitive screening techniques 
resulted in the detection of smaller tumors in earlier stages of disease 1, 2, which are more 
amendable to local therapy. This is of special importance in the aging population of cancer 
patients, in which comorbidity and reduced tolerance of treatment-related adverse effects 
often limit the application of major surgery or systemic therapy 3, 4. Additionally, the concept 
of achieving long-term tumor control favours local ablative therapy of selected lesions in 
order to postpone or complement systemic therapy.  
Local ablative therapies aim to induce cell death within a limited and confined range from 
application 5, either with an curative intent or to create a margin for improved local tumor 
control. These modalities exploit thermal energy-based cell death (radiofrequency ablation 
(RFA), microwave ablation (MWA), high-intensity focused ultrasound (HIFU) and cryo-
ablation), electric energy-based cell death (irreversible electroporation (IRE), radiation 
energy-based cell death (e.g. glass or resin microspheres filled with beta-emitting 
radioisotopes [90Y] or [166Ho]) or chemical induced cell-death (trans-arterial 
chemoembolisation (TACE) or percutaneous ethanol injection therapy (PEIT)). Recent well-
designed randomized controlled trials demonstrate that local ablative therapy comes of age. 
For example, the CLOCC study demonstrated that curative RFA can provide an alternative 
treatment option to resection for small-sized colorectal liver metastases 6. The SIRFLOX 
study showed that addition of 90Y-radioembolisation to chemotherapy in liver-dominant 
metastatic colorectal cancer delayed disease progression in the liver 7.  
For various tumor types, these local ablative therapies have become part of clinical practice; 
e.g. RFA for liver and lung metastases, [90Y]-radioembolisation for primary hepatocellular 
carcinoma and colorectal liver metastases or cryoablation in non-small cell lung cancer or 
renal cancer 8, 9. However, to establish local ablative therapy in current clinical practice, 
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accurate tools to exactly measure the effectiveness of local ablative therapy on the tumor 
viability are mandatory.  
Anatomical imaging techniques, such as contrast-enhanced computed tomography (ceCT) or 
dynamic contrast enhanced (DCE) or diffusion-weighted (DW) magnetic resonance imaging 
(MRI), respectively assess changes in tumor size, perfusion and permeability and tissue 
composition. Most guideline supported response criteria are based on changes of lesion size 
with or without evaluation of lesion density or enhancement characteristics, and the 
appearance of new lesions 10-16. However, many studies have adapted these criteria or 
empirically established new criteria, with the intent to increase their accuracy in evaluating 
responses to local ablative therapy. Importantly, the effect of ablative therapy is not selective 
to tumor cells but affects stromal and local healthy cells to similar extent. Consequently, local 
ablative therapy may in most cases induce necrosis, cystic degeneration, haemorrhagic 
and/or oedematous changes in the tissue 17-20, which might initially result in enlargement of 
the lesion, while the final change in volume takes weeks or month to occur. Moreover, 
previous local and systemic therapies in cancer patients can affect the appearance of normal 
parenchyma 21, 22. For these reasons, anatomical criteria have consistently shown to 
underestimate the anti-tumor effect of local ablative therapies. In addition, changes in lesion 
enhancement, density or diffusion characteristics might in most cases not reflect actual 
pathological tumor responses especially at early stages 23-25. 
On the other hand, metabolic changes at the cellular level have demonstrated to precede 
changes in tumor size or tissue parameter; e.g. in RFA the earliest cellular events are loss of 
mitochondrial enzymes and lactate dehydrogenase activity 17. A sharp decrease in glycolytic 
activity can thus be expected. Within the first days, it is followed by coagulation necrosis, 
tissue dehydration and recruitment of a variety of inflammatory immune cells 5. Accurate 
information on the efficacy of local ablative therapy early after application is of paramount 
importance for treatment planning and implementation of systemic therapy. Studies on the 
role of [18F]FDG PET/CT to monitor the effect of local ablative therapies are increasing, but 
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vary largely in study design, number of patients, time point of imaging, criteria for response 
and choice of comparator modality.  
This study systematically reviews the currently available literature on [18F]FDG PET/CT to 
monitor the efficacy of local ablative therapies. By including all local ablative treatment 
modalities, tumor types and organ sites, we aim to provide a comprehensive overview of 
current status, identify general patterns across studies and provide recommendations for 
future studies and clinical practice.  
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METHODS: 
 
Search strategy 
To identify all relevant publications, we performed systematic searches in PubMed and in the 
Cochrane Library, using the following search terms (("Ablation Techniques"[Mesh] OR 
radioembolization OR radioembolisation OR Y90 OR Y-90 OR 90Y OR 166Ho OR Ho-166 or 
Ho166 OR chemoembolization OR chemoembolisation OR radiofrequency ablation OR RFA 
OR radio frequency ablation OR cryoablation OR microwave ablation OR HIFU OR high 
intensity focused ultrasound OR high-intensity focused ultrasound)) AND ("Positron-Emission 
Tomography"[Mesh] OR PET OR PET/CT OR fluorodeoxyglucose OR fluorine-18-
deoxyglucose OR fluoro-deoxyglucose OR 18F-FDG OR F-18-FDG OR FDG). The 
references of the identified articles were searched for relevant publications. The Cochrany 
Library search yielded no relevant additional results. Approval of the institutional review 
board for this literature review was waived. 
 
Selection process  
Two reviewers (EA and LH) independently screened all potentially relevant abstracts for 
eligibility obtained from the database search. Studies were not restricted to anatomical sites 
or tumor type and were included if: 
a. the study investigated the performance of [18F]FDG PET/CT or [18F]FDG PET for 
treatment monitoring 
b. the study involved human subjects 
c. the study involved local ablative therapies, including;  
(i) radiofrequency ablation 
(ii) cryoablation 
(iii) microwave ablation 
(iv) high intensity focussed ultrasound 
(v) [90Y]-radioembolisation, [166Ho]-radioembolisation 
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(vi) chemoembolisation 
d. the study reports clinical outcome 
e. English version of the manuscript was available 
 
Full-text articles of these selected records were obtained and excluded from this study when:  
investigational drugs or techniques are exploited, when publication type did not include 
original data (e.g. reviews, editorials, letters, legal cases, interviews, case reports, comments 
and follow-up reports from previous cohorts), when <15 evaluable patients with [18F]FDG 
PET/CT were reported and when there was a wide spread in imaging time-points. 
Differences in judgment were resolved by consensus procedure. 
All articles were scored using the QUADAS system (supplementary table 5).  
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RESULTS: 
 
Search results 
The literature search performed in September 2017 generated a total of 727 records, of 
which 559 studies were excluded based on screening of the abstract. Main reasons for 
exclusion were a) PET imaging was used for dosimetry, b) study did not involve local ablative 
therapy or c) [18F]FDG was not used for monitoring but for diagnostic purposes, or a 
combination of these criteria. The full text of the remaining 168 records was screened for 
eligibility, of which 52 studies were included in this review. Main reasons for exclusion were 
a) no full text available, b) no data on clinical outcome was reported, c) study involved 
investigational drug or procedure, d) publication type, e) study involved <15 patients or f) 
varying time points of imaging. 
Five studies report [18F]FDG PET/CT results to evaluate technical treatment success; 47 
studies report results of early time points to evaluate treatment efficacy. In the supplementary 
data, tables 1-4 summarize the data from the selected reports (table 1 and 2 immediate time 
points and table 3 and 4 later time points). Most studies involve only limited numbers of 
patients and are retrospective in design. Moreover, imaging time points and imaging 
evaluation criteria are highly variable across studies. Table 5 summarizes the studies 
according to the QUADAS criteria, studies with no or one minor comment (indicated in 
orange) are discussed in the text, studies with two or more minor comments or one major 
comment are not discussed but their results are included in Table 1-4.  
 
Immediate [18F]FDG PET/CT imaging to evaluate technical treatment success 
Similar to surgical resection with curative intent, cornerstone of successful local ablative 
therapy is to achieve complete tumor destruction with oncological clear margins, particularly 
in RFA, microwave and cryoablation. Anatomical imaging modalities have so far not been 
adequate to assess of vital tumor residue 18-20; intra-operative biopsies are highly informative 
but not feasible in most settings 26. The shutdown of pathways involved in glucose 
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metabolism can serve as an early measure of therapy-induced cell death 17, 27. For tumors 
that appear as 18F-FDG avid on preoperative imaging, functional imaging with [18F]FDG 
during or immediately after the procedure has been investigated as a tool to measure 
technical treatment success. To this end, the standard [18F]FDG dose can be split in two 
doses, the first dose just prior to procedure for treatment planning and a second dose to 
identify residual viable tumor before inflammatory changes occur (e.g. split-dose protocol). 
Such approach facilitates additional treatment in the same session and potentially increases 
treatment efficacy 28.   
Five studies 28-32 (in total 145 patients) evaluated the prospective value of [18F]FDG PET/CT 
<24 hours after treatment with thermal ablation (4x RFA, and 1x RFA/MWA) in liver 
metastases (tables 1 and 2). All five reported visual interpretation of the [18F]FDG PET/CT 
and three studies also reported quantitative analyses (SUVmax or tissue radioactivity 
concentration (TRG)). All found a good accuracy of [18F]FDG PET/CT in predicting local 
tumor residue or local tumor progression. Ryan et al. exploited a split-dose approach and 
identified focal uptake immediately after RFA in one (out of 23) patient, which was confirmed 
to be viable tumor tissue, and this patient received additional treatment. In 2/22 patients with 
a negative [18F]FDG PET/CT follow-up, imaging detected local recurrence 28. The lowest 
reported sensitivity of immediate [18F]FDG PET/CT was in the study of Vandenbroucke et al.: 
63% (combining nodular and rim like uptake to detect viable tumor localisation) 30. Two other 
studies reported an accuracy above 90% and superiority compared to ceCT 31, 32. One study 
found no significant difference compared to the sensitivity and specificity of MRI 31. 
 
Response monitoring to evaluate treatment efficacy 
Correct assessment of responses to local ablative therapy at early time points after the 
procedure is vital for early response adapted treatment strategies, especially if local ablative 
therapy is used in addition to other treatment modalities 33.  
However, the necrotic, cystic and haemorrhagic changes induced by local ablative therapies 
evoke inflammatory responses in the lesion and surrounding healthy tissue in the days to 
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weeks following procedure. Histologic changes include a central zone of necrosis surrounded 
by a zone of inflammation caused by the recruitment of neutrophils, lymphocytes, and 
macrophages 17, 18, 34. Whereas ceCT and DWI-MRI techniques are hindered by abnormal 
enhanced patterns, [18F]FDG PET/CT may also be confounded by these inflammatory 
changes during the post-ablation healing process.  
Response monitoring up to several months after intervention might be influenced by 
inflammation, however [18F]FDG PET/CT still seems more sensitive for treatment effect and 
detection of local recurrence. 
 
RFA and cryoablation in liver metastases  
Four studies (total 111 patients) evaluated [18F]FDG PET/CT <1 month after 
RFA/cryoablation in liver metastases (tables 3 and 4) 35-38. All four studies showed a higher 
sensitivity of [18F]FDG PET/CT to detected local recurrence compared to CT and/or MRI. 
False positive findings can be due to inflammation or abscess formation, though reported 
specificity was high: 80%-100%. The study of Joosten et al. showed that [18F]FDG PET/CT 
within 3 weeks of treatment, correctly predicted 6/7 recurrences 35.  
 
RFA and cryoablation for lung lesions 
In settings of RFA for lung metastases or primary lung cancer, the clinical utility might be 
different than for liver lesions (tables 3 and 4); as reported in 8 studies (in total 402 patients). 
Four other studies did not meet the QUADAS criteria. Deandreis et al., observed a poor 
specificity: [18F]FDG PET/CT was true positive in 3/7 patients, particularly with nodular 
pattern, and 4/7 were false positive 39. Higuchi et al. 40 and Higaki et al. 41 report in similar 
sized prospective series that imaging <1 month after RFA did not correlate with local tumor 
progression at later time points. The study by Yoo et al. in 26 patients with irresectable 
primary non-small cell lung cancer who underwent RFA 42, [18F]FDG PET/CT performed 
within 4 days was not predictive of 1-year event. But [18F]FDG PET/CT at 6 months 
corresponded better with outcome 1 year after intervention 42. Multiple studies confirm the 
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higher diagnostic accuracy for [18F]FDG PET/CT from 3 months after intervention, as 
compared to CT 43-45. A continuous decrease in SUVmax from intervention to 3 months and 6 
months was identified as physiological pattern, with high negative predictive value. An 
increase in [18F]FDG uptake or absolute [18F]FDG uptake of SUVmax >2.5 has been 
suggested to predict recurrence 45.  
 
Regional ablative therapy in hepatocellular carcinoma 
Five studies (in total 142 patients) report on the role of [18F]FDG PET/CT in regional ablative 
therapy for hepatocellular carcinoma, four other studies did not meet the QUADAS criteria. In 
a retrospective study on 33 patients with hepatocellular carcinoma treated with 90Y-
microspheres, Habet et al. found that patients with a response on [18F]FDG PET/CT had a 
significantly better overall survival than metabolic non-responders, 10 months versus 5 
months 46. Similar observations stem from the retrospective analyses of 27 patients by Ma et 
al.; [18F]FDG PET/CT 4-6 weeks after treatment decrease of 90% in tumor SUVmax as 
compared to baseline, resulted in a sensitivity of 100% and specificity of 92,5% 47. 
Responders according to this criterion had longer time-to-progression, 18.3 months versus 
7.1 months. 18F-FDG-PET/CT responses correlate to responses assessed by modified 
RECIST, but tend to occur earlier. Paudyal et al. investigated the use of [18F]FDG PET/CT 
during follow-up and showed that recurrence was also detected earlier on PET/CT than ceCT 
48
. Li et al. showed in 22 patients that a negative [18F]FDG PET/CT after TACE with or w/o 
bevacizumab correlated with overall survival, whereas imaging with [11C]acetate PET 
performed slightly worse 49.  
 
Radioembolisation in liver metastases 
The role of [18F]FDG PET/CT after radioembolisation for liver metastases is mostly studied: 3 
studies report results of imaging <1 month after treatment 50-52 and 12 studies report on 
imaging at >1 month after treatment 53-62 (in total 563 patients, table 3 and 4). Four other 
studies did not meet the QUADAS criteria. All studies with [18F]FDG PET/CT within 1 month, 
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showed a strong correlation between metabolic response and outcome. One study showed 
that PET was able to detect more responses than CT, but did not analyse the correlation 
between of PET-response and survival 50. The study of Michl et al., imaging at 3 months 
reported a high correlation of [18F]FDG PET/CT findings with survival and observed no 
correlation between CT response and survival 55. In line with this study, the other studies 
imaging >1 month after radioembolisation found a high correlation between metabolic 
response and survival 53, 54, 63-66, which are not identified by anatomical imaging using 
RECIST 66.  
For example, Fendler et al. prospectively studied [18F]FDG PET/CT in 80 patients with liver 
metastases from colorectal cancer at 3 months after [90Y]-microspheres treatment 53. As 
opposed to RECIST1.1 criteria or SUV, the PET measures metabolic tumor volume and total 
lesion glycolysis were predictive of overall survival. In patients with a decrease of >30% in 
metabolic tumor volume (MTV) (27/80 patients) overall survival was 92 weeks, significantly 
better than in non-responders (49 weeks). Slightly less predictive was a >30% decrease in 
total lesion glycolysis (TLG); in 30/80 responding patients, overall survival was 91 weeks 
versus 48 weeks in non-responders. Similar findings by Shady et al. support this notion that 
volume-based parameters have better prognostic impact over single-voxel measures 65. A 
retrospective analysis of 17 patients with liver metastases from pancreatic cancer who 
underwent [90Y]-radioembolisation report that >30% decrease in either SUVpeak or the TLG 
(according to PERCIST criteria) identified the same patients as complete or partial 
responders 55.  
 
Radioembolisation in cholangio carcinoma 
Haug et al. used [18F]FDG PET/CT at 3 months after [90Y]-microspheres for intra-hepatic 
cholangio carcinoma to predict survival, in comparison to MR based responses 67. They 
show in 26 patients that, in contrast to changes in SUV, a decrease in MTV is an 
independent predictor of overall survival (hazard ratio 0.20). Along this line, the prospective 
study in 17 patients with intra-hepatic cholangio carcinoma by Filippi et al. demonstrates that 
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a decrease in TLG of >50% within 6 weeks after treatment is significantly associated with 
both longer time-to-progression (36.9 versus 13.7 weeks) as well as improved overall 
survival (79.6 versus 43.1 weeks) 68. 
 
DISCUSSION: 
 
In general, studies suggest that [18F]FDG PET/CT indicates local tumor progression at an 
earlier time point after treatment as compared to other imaging modalities. In solid organs, 
absent or a markedly decreased [18F]FDG uptake in the lesion after local ablative treatment 
as measured by SUVmax indicates successful ablation. Moderate uptake in a homogeneous 
rim like pattern is accepted as physiological and caused by tissue remodelling and scar 
formation. Inadequate decrease of [18F]FDG uptake in the lesion after ablation marks 
residual vital tumor, as well as focal or multifocal [18F]FDG uptake in the margins of the 
ablation zone. Similarly, an increase in [18F]FDG uptake, whether immediate or after an initial 
decrease, always indicates residual or recurrent disease. PERCIST criteria of at least 30% 
decrease in SUVmax appears to be a safe cut-off for response. Parameters that incorporate 
tumor volume as well (MTV and TLG) do not prevail over SUVmax, but might reflect that larger 
tumor lesions are prone to incomplete ablation. These response characteristics are valid for 
the included local ablative modalities and different tumor types, provided that the lesions are 
more [18F]FDG-avid than the surrounding tissue at baseline. For solid organs these criteria 
apply to early first imaging time points; within one month after therapy. To avoid false positive 
results, we would suggest 2-4 weeks. If false positive findings are encountered, can be 
caused by abscesses in the appropriate clinical context, which typically present with a rim 
like markedly increased [18F]FDG uptake pattern.  
Assessment of treatment of lung lesions differs from evaluation of treatment in solid organs. 
From an imaging perspective, lung parenchyma has different characteristics that impact the 
assessment of reactive changes in adjacent normal tissue to local tumor destruction. The 
target lesions, metastases and primary lung cancers, are solid and most likely respond 
similar to lesions located in solid organs. Surrounding normal lung parenchyma contains 
 14
much less numbers of cells, reflected by a low physiologic rate of glycolysis (normal SUVmax 
0.6-0.7) 69 and a very low density (Hounsfield units approx. -800). Furthermore, the 
composition of lung parenchyma is different from solid organs; mostly endothelial cells and 
immune cells, less stromal cells and extracellular matrix. Thus early responses to local 
ablative treatment, with coagulation of proteins, interstitial oedema and influx of immune 
cells, rapidly results in profound increases in [18F]FDG uptake and appear as increased 
density in normal lung parenchyma. Bearing this in mind, not only the absence of [18F]FDG 
uptake, but also high uptake at the pleural border of a treated lesion and intense focal uptake 
located at the site of the lesion was not associated with recurrence, in most cases resemble 
profound inflammatory responses and organizing pneumonia or granuloma formation, 
respectively. However, moderate uptake and rim like uptake with intense focal uptake are 
indicative of incomplete tumor ablation or recurrence.  
Also for lesions located in the lung parenchyma, the PERCIST criterion >30% decrease in 
SUVmax appears reasonable to define response and SUVmax >3 is highly suggestive of 
residual or recurrent tumor. No differences were observed with regard to the histological 
subtype or primary tumor. Opposite to lesions treated in solid organs, most studies 
demonstrate that imaging within the first 3 months after local ablation yields unspecific 
findings that have no predictive impact. Therefore, first imaging time point >3 months is 
suggested.  
As exemplified by our tabulated data, the heterogeneity of the studies that evaluate 
[18F]FDG-PET/CT to monitor responses to local ablative therapy is a limitation to extract 
evidence-based data that underpin the wide scale application of [18F]FDG PET/CT for these 
indications. Most studies have a relatively small sample size and are retrospective in nature, 
impacting on the power of the data. Furthermore, in absence of a generally accepted non-
invasive gold standard, studies differ greatly with respect to the comparator, while 
histopathological confirmation of imaging results was included in only a small minority of 
studies. Given the heterogeneity of the protocols that generated the available data, we chose 
to accept all tumor types and local ablative modalities and techniques, as well as disease 
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localisation, in order to identify general patterns for optimally use of [18F]FDG PET/CT as 
imaging modality for monitoring local ablative therapies. 
Another limitation is the extrapolation of data from earlier studies using equipment which in 
current clinical practice has been replaced by more advanced technology. A striking example 
is the replacement of stand-alone PET devices by integrated high-resolution PET/CT 
scanners, which revolutionized the impact of molecular imaging. The same holds true for 
modern CT and MRI. For example, ADC-mapping and whole body MRI have found their way 
into clinical practice. Additionally, new software tools for analysing data such as texture 
analysis allow characterization of lesions beyond anatomical changes. Further developments 
such as integrated PET/MRI may again increase the potential for optimal, early assessment 
of treatment response.  
It is well appreciated that [18F]FDG is the radiopharmaceutical of choice for a wide variety of 
indications. Nevertheless, being a rather non-specific agent, targeting not only tumor cells 
but also therapy-induced inflammation, the development of tumor-specific 
radiopharmaceuticals such as radiolabeled peptides and antibodies may further increase the 
accuracy by selectively depicting residual or recurrent tumor.  
In conclusion, data in literature suggest that [18F]FDG PET/CT is a highly accurate tool to 
identify successful minimal invasive local treatment, to identify residual or recurrent tumor 
early and to provide prognostic and predictive information. However, prospective 
interventional studies based on [18F]FDG PET/CT findings of disease activity are still scarce. 
Furthermore, the optimal timing of [18F]FDG PET/CT after treatment may vary on the 
localization of disease, allowing (very) early imaging in solid organs as the liver, while post-
treatment inflammation in the lung parenchyma is a challenge in the first 3 months after 
therapy. Uniform, quantitative criteria for the assessment PET such as PERCIST are needed 
to allow more accurate comparison of literature data.  
 
NOTEWORTHY: 
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1. [18F]FDG PET/CT is a highly accurate tool to identify residual or recurrent tumor 
immediately after local ablative therapy.  
2. Increase or inadequate decrease, as per PERCIST, of [18F]FDG uptake in the lesion after 
ablation, as well as focal or multifocal [18F]FDG uptake in the margins of the ablation zone 
are highly indicative of residual or recurrent disease. 
3. The optimal timing of [18F]FDG PET/CT after treatment may vary on the localization of 
disease, allowing (very) early imaging in solid organs as the liver, while post-treatment 
inflammation is a challenge in the first 3 months after therapy in the lung parenchyma. 
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TABLE 1. Summary of studies with imaging <24 hours to evaluate technical treatment success  
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therapy 
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t 2 
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therapy 
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timepoint 
+ 
comparator 
imaging 
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criteria for 
PET 
evaluation 
clinical 
endpoint 
clinical 
outcome 
measure 
QUAD
AS 
criteria 
met 
Cornelis et 
al. J Nucl 
Med 2016 
thermal 
ablation 
(RFA or 
microwave) 
liver 
metastases 
from 
different 
primary 
tumors 
n=21 retro-
spective 
no immedia
te 
- - no ceCT visual, 
tissue 
radioactivi
ty 
concentrat
ion (TRC) 
1-year 
tumor 
response 
follow-up, 
ceCT 
 yes 
Vandenbrouc
ke et al. J 
Vasc Interv 
Radiol 2014 
RFA liver 
metastases 
n=20  n/a  no 24 hours - - - ceCT visual, 
predefine
d patterns 
tumor 
response 
follow-up, 
PET/CT 
yes 
Kuehl et al. 
Clin Oncol 
2008 
RFA liver 
metastases 
colorectal 
and 
hepatocellul
ar 
carcinoma 
n=55  retro-
spective 
yes <24 
hours 
1 month 3 months yes ceCT SUVmax, 
visual 
local 
tumor 
progressio
n 
histology, 
or ceCT 
and 
follow-up 
yes 
Kuehl et al. 
Eur J Radiol 
2008 
RFA liver 
metastases 
from 
colorectal 
cancer 
n=16 pro-
spective 
yes <24 
hours 
4 weeks 3 months - PET alone, 
MR 
SUVmax, 
visual 
local 
tumor 
progressio
n 
histology, 
or ceCT 
and 
follow-up 
yes 
Ryan et al. 
Radiology 
2013 
RFA liver 
metastases 
from 
different 
primary 
tumors 
n=23 retro-
spective 
yes immedia
te 
- - - no visual local 
tumor 
progressio
n 
most 
recently 
available 
follow-up 
CT, MR, or 
PET  
yes 
  
TABLE 2. Main results of studies with imaging <48 hours to evaluate technical treatment success  
author local therapy tumor type nr of 
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met 
Cornelis et 
al. J Nucl 
Med 2016 
thermal 
ablation 
(RFA or 
microwave) 
liver 
metastases 
from 
different 
primary 
tumors 
n=21 11 of the 25 tumors recurred within 1 year.  
The accuracy of the qualitative analysis of FDG PET was 92% (23/25) (P < 0.001), and the area under 
the ROC curve was 0.929 (95% CI, 0.740-0.990). 
Immediate PET/CT accurately predicts the success of liver metastasis ablation at 1 year and is superior 
to immediate contrast enhanced CT. 
y
e
s 
Vandenbrouc
ke et al. J 
Vasc Interv 
Radiol 2014 
RFA liver 
metastases 
n=20 Nodular enhancement and rim-like enhancement together had the highest sensitivity to detect viable 
tumor localisation (63% and 48% respectively). Nodular enhancement had the highest specificity. 
yes 
Kuehl et al. 
Clin Oncol 
2008 
RFA liver 
metastases 
colorectal 
and 
hepatocellul
ar 
carcinoma 
n=55 35/78 tumors showed local tumor progression (LTP) 
There was no significant difference in the mean time until the detection of local tumor progression: 4.1 
± 3 months when PET/CT was used and 5.85 ± 4.6 months when using contrast-enhanced computed 
tomography (P > 0.11). 
PET/CT supports RFA by early identification of residual tumor or LTP. 
yes 
Kuehl et al. 
Eur J Radiol 
2008 
RFA liver 
metastases 
from 
colorectal 
cancer 
n=16 The accuracy and sensitivity for tumor detection was 86% and 76% for PET alone, 91% and 83% for 
PET/CT and 92% and 75% for MRI, respectively. 
In comparison to PET alone, PET/CT was significantly better for detecting LTP after RFA. There were 
no significant differences between MRI and PET/CT, but these preliminary results need further 
verification. 
yes 
Ryan et al. RFA Liver 
metastases 
from 
different 
primary 
tumors 
n=23 28 (97%) of the ablated lesions showed no residual FDG activity directly after RFA. One patient with 
residual activity underwent immediate biopsy that revealed residual viable tumor and was immediately 
re-treated.  
Follow-up imaging showed local recurrences in two (7%) lesions that were negative at PET 
immediately after ablation. 
yes 
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pts 
study 
design 
baseline 
imaging 
post-
therapy 
timepoi
nt 1 
post-
therap
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timepoi
nt 2 
post-
therapy 
timepoint 3 
post-
therapy 
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imaging 
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criteria 
for 
PET 
evaluat
ion 
clinical 
endpoint 
clinical 
outcome 
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QUADAS 
criteria 
met 
indication: RFA and cryoablation in liver metastases   
Joosten et al. 
Eur J Surg 
Oncol 2005 
RFA and 
cryo-ablation 
w/ or w/o 
resection 
liver 
metastases 
from 
colorectal 
cancer 
n=43  retro-
spective 
 <3 
weeks 
6 
weeks 
3 months yes ceCT visual  follow-
up 
yes 
Langenhoff 
et al. J Clin 
Oncol 2002 
RFA and 
cryo-ablation 
w/ or w/o 
resection 
liver 
metastases 
from 
colorectal 
cancer 
n=23 pro-
spective 
yes <3 
weeks 
6 
weeks 
3 months 6 months ceCT visual local 
recurrence 
follow-
up and 
tumor 
marker 
yes 
Donckier et 
al. J Surg 
Oncol 2003 
RFA liver 
metastases 
 
n=17 pro-
spective 
yes 1 week 1 
month 
3 months yes ceCT visual local 
recurrence  
follow-
up 
and/or 
histology 
yes 
Chen et al. 
Ann Nucl 
Med 2013 
RFA primary 
liver tumor 
or 
metastases 
n=28 retro-
spective 
no <8 
weeks 
- - - ceCT, MR visual local 
recurrence 
follow-
up, 
ceCT, 
PET, 
MR 
yes 
Nielsen et al 
Eur J Radiol 
2013 
RFA liver 
metastases 
from 
colorectal 
cancer 
n=79 retro-
spective 
Yes <1 year - - - ceCT Visual local 
recurrence 
ceCT no 
Sahin et al. 
Ann Surg 
Oncol 2012 
RFA liver 
metastases 
from 
n=104 retro-
spective 
yes variable 
(media
n 12 
- - - ceCT not 
specifi
ed 
local 
recurrence, 
overall survival 
ceCT, 
follow-
up 
no 
colorectal 
cancer 
months
) 
indication: RFA and cryoablation for lung lesions  
Yoo et al. Am 
J Roentgenol 
2011 
RFA irresectable 
primary 
non-small 
cell lung 
cancer 
n=30  yes 4 days 
(n=26) 
6 
month
s 
(n=23) 
- no no SUVm
ax 
1-year clinical 
event 
follow-
up, 
ceCT 
Yes 
Lafuente et 
al. Rev Esp 
Med Nucl 
Imagen Mol 
2016 
RFA lung 
metastases 
colorectal 
cancer 
n=18 pro-
spective 
yes 1 
month 
3 
month
s 
- - no SUVm
ax and 
retenti
on 
index 
local 
recurrence 
histology No 
Deandreis et 
al. Radiology 
2011 
RFA lung 
carcinoma 
or lung 
metastases 
n=34 pro-
spective 
yes (24 hrs) 1 
month 
3 months yes ceCT SUVm
ax, 
visual 
local 
recurrence 
follow-
up 
Yes 
Higuchi et al. 
J Cancer Res 
Clin Oncol 
2014 
RFA lung 
carcinoma 
or lung 
metastases 
n=20 pro-
spective 
yes 7-14 
days 
3-6 
month
s 
- - ceCT 
(RECIST) 
visual local 
recurrence, 2-
yr OS 
 Yes 
Higaki et al. 
Ann Nucl 
Med 2008 
RFA lung 
carcinoma 
or lung 
metastases 
n=15 pro-
spective 
yes 0-3 
months 
3-6 
month
s 
6-9 months - ceCT SUVm
ax 
 follow-
up 
Yes 
Alafate et al. 
Acta Med 
Okayama 
2013 
RFA lung cancer 
or lung 
metastases 
n=25 retro-
spective 
Yes 3 
months 
6 
month
s 
- - ceCT  SUVm
ax 
tumor 
response 
follow-
up 
No 
Wang et al. 
Int J Clin Exp 
Med 2015 
RFA lung 
metastases 
from - lung 
carcinoma 
58 pro-
spective 
Yes 3 
months 
9 
month
s 
12 months yes ceCT SUVm
ax 
local 
recurrence 
follow-
up 
Yes 
Bonichon et 
al. Eur J Nucl 
Med Mol 
RFA lung 
metastases 
n=89 pro-
spective 
Yes 3 
months 
- - - ceCT SUVm
ax 
local 
recurrence 
ceCT yes 
Imaging 2013 
Singnurkar et 
al. J Nucl 
Med 2010 
RFA lung 
carcinoma 
or lung 
metastases 
n=68 
(56 
adequ
ate 
imagin
g) 
retro-
spective 
Yes 1-4 
months 
6-12 
month
s 
- - ceCT SUVm
ax, 
visual 
local 
recurrence 
follow-
up 
No 
Suzawa et al. 
Clin Nucl 
Med 2013 
RFA lung 
carcinoma 
or lung 
metastases 
n=143 retro-
spective 
No 3 
months 
6 
month
s 
9 months yes ceCT SUVm
ax 
local 
recurrence 
follow-
up, 
histology 
Yes 
LoGiurato et 
al. Nucl Med 
Commun 
2015 
cryoablation non-small 
cell lung 
cancer 
n=28 retro-
spective 
yes 
(n=19 
lesions) 
6 
months 
(n=23) 
or 12 
months 
(n=4) 
12 
month
s 
18 months 24 months CT SUVm
ax 
local 
recurrence 
PET/CT 
and CT 
Yes 
indication: regional ablative therapy in hepatocellular carcinoma  
Higashi et al. 
Eur J Nucl 
Med Mol 
Imaging 2010 
TACE, TAC, 
RFA or 
systemic 
chemo-
therapy 
hepato-
cellular 
carcinoma 
n=60 - retro-
spective 
yes <1 month -  - - no SUVm
ax, 
visual 
 follow-
up, 
tumor 
markers 
No 
Sabet et al. 
Nuklearmedi
zin 2014 
Y-90 
microspheres 
hepato-
cellular 
carcinoma 
n=33 retro-
spective 
yes 4 weeks - - - no SUVm
ax 
overall survival follow-
up 
Yes 
Ma et al. 
Theranostics 
2014 
TACE hepato-
cellular 
carcinoma 
n=27 retro-
spective 
Yes 4-6 
weeks 
- - - ceCT 
(mRECIST) 
SUVm
ax 
overall 
survival , time 
to progression 
follow-
up, 
ceCT 
Yes 
Kim et al. 
Nucl Med 
Mol Imaging 
2012 
RFA, TACE 
or ethanol 
injection 
hepato-
cellular 
carcinoma 
n=31 retro-
spective 
no <1 month - - - no SUVm
ax, 
visual 
local 
recurrence 
follow-
up with 
ceCT 
and 
tumor 
marker 
No 
Paudyal et al. RFA hepato- n=24 pro- yes 3 months 6 9 months yes ceCT SUVm local follow- yes 
Oncol Rep 
2007 
cellular 
carcinoma 
spective mont
hs 
ax recurrence  up 
Li et al. Eur J 
Nucl Med 
Mol Imaging 
2017 
TACE (+/-
bevacizumab
) 
hepato-
cellular 
carcinoma 
n=22 pro-
spective 
yes 10 weeks    11C-
Acetate 
PET, 
CT 
(RECIST) 
Metab
olic 
respon
se 
overall survival follow-
up 
Yes 
Cascales-
Campo et al. 
Transplant 
Proc 2015 
TACE hepato-
cellular 
carcinoma 
undergoing 
orthotopic 
liver 
transplantat
ion 
n=20 retro-
spective 
yes Variable 
interval 
after 
TACE 
(<8 
weeks 
before 
liver 
transplan
t) 
- - - No SUVm
ax 
tumor 
response, 
survival rate 1-
year and 3-
year 
histology
, follow-
up 
No 
Song et al. 
Clin Radiol 
2015 
TACE hepato-
cellular 
carcinoma 
n=73 retro-
spective 
no variable 
(mean 41 
days) 
- - - ceCT ratio 
SUVm
ax 
tumor 
to 
SUVm
ean 
liver 
treatment 
success, 
overall survival 
follow-
up, 
ceCT, 
tumor 
marker 
No 
Wang et al. J 
Dig Dis 2013 
status after 
surgery 
and/or RFA 
recurrence 
of hepato-
cellular 
carcinoma 
n=36 pro-
spective 
no varying 
<2-3 
months 
- - - ceUS visual local 
recurrence  
biomark
er, 
histology
, follow-
up 
Yes 
indication: radioembolisation in liver metastases  
Miller et al. 
Am J 
Roentgenol 
2007 
Y-90 
microspheres 
liver 
metastases 
from 
different 
primary 
tumors 
n=23  retro-
spective 
yes <30 days 60 
days 
90 days yes CT (WHO, 
RECIST, 
necrosis) 
visual tumor respons follow-
up 
Yes 
Gulec et al. 
Eur J Nucl 
Med Mol 
Imaging 2011 
Y-90 resin 
microspheres 
liver 
metastases 
from 
colorectal 
cancer 
n=20 pro-
spective 
yes 4 weeks - - - no functio
nal 
tumor 
volume
, TLG 
overall survival follow-
up 
Yes 
Sabet et al. 
Eur J Nucl 
Med Mol 
Imaging 2015 
Y-90 
microspheres 
liver 
dominant 
metastatic 
colorectal 
cancer 
n=51 retro-
spective 
yes 4 weeks - - - no SUVm
ax, 
ratio 
SUVm
ax to 
liver 
(>50% 
decrea
se) 
overall survival follow-
up 
Yes 
Kalva et al. 
Am J Clin 
Oncol 2017 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=45 retro-
spective 
yes 45 days 
(n=35) 
6 
mont
hs 
9 months yes ceCT 
and/or MR 
(RECIST) 
PERCI
ST 
overall survival follow-
up 
No 
Fendler et al. 
J Nucl Med 
2013 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=80 pro-
spective 
yes 3 months - - - ceCT 
(RECIST 
1.1) 
MTV, 
TLG, 
SUVm
ax, 
SUVpe
ak 
overall survival follow-
up 
Yes 
Fendler et al. 
J Nucl Med 
2016 
Y-90 micro-
pheres 
liver 
metastases 
from breast 
cancer 
n=81 retro-
spective 
yes 3 months 6 
mont
hs 
(n=3
0) 
9 months 
(n=30) 
yes no SUVm
ax 
(>30% 
decrea
se) 
treatment 
response, 
overall survival 
follow-
up, 
tumor 
marker 
Yes 
Haug et al. J 
Nucl Med 
2012 
Y-90 micro-
spheres 
liver 
metastases 
from breast 
cancer 
n=58  yes 3 months - - - ceCT and 
MR 
(RECIST) 
SUVm
ax 
(PERC
IST) 
overall survival follow-
up 
No 
Michl et al. J 
Nucl Med 
2016 
Y-90 micro-
spheres 
liver 
metastases 
from 
n=17 retro-
spective 
yes 3 months - - - ceCT 
(RECIST) 
SUVpe
ak, 
TLG 
overall 
survival, 
progression 
follow-
up, 
ceCT/M
yes 
pancreatic 
cancer 
(PERC
IST) 
free survival, 
intrahepatic 
progression 
R, tumor 
markers 
Sofocleous et 
al. Clin 
Colorectal 
Cancer 2014 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=19 pro-
spective 
yes, in 
15/19 
patients  
4-8 
weeks 
3-4 
mont
hs 
5-6 months yes ceCT 
(RECIST) 
PERCI
ST 
liver-PFS, 
PFS, OS 
follow-
up, 
ceCT  or 
MR, and 
tumor 
markers 
Yes 
Sofocleous et 
al. Clin 
Colorectal 
Cancer 2015 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=53 retro-
spective 
yes 4-8 
weeks 
12-
16 
week
s 
- - ceCT 
(RECIST) 
SUVm
ax 
(PERC
IST) 
tumor 
response 
follow-
up 
No 
Szyszko et 
al. Nucl Med 
Commun 
2007 
Y-90 micro-
spheres 
liver 
metastases 
different 
primary 
tumors 
n=21 pro-
spective 
yes 6 weeks 6 
mont
hs 
12 months - ceCT 
(RECIST) 
SUVm
ax 
tumor 
response 
follow-
up, 
ceCT 
Yes 
Zerizer et al. 
Eur J Nucl 
Med Mol 
Imaging 2012 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=25 pro-
spective 
yes 6-8 
weeks 
- - - ceCT 
(RECIST, 
Choi) 
EORT
C 
criteria 
2-year PFS 
(excluding 
extrahepatic 
progression) 
follow-
up, 
tumor 
markers 
Yes 
Bagni et al. 
Cancer 
Biother 
Radiopharm 
2015 
Y-90 micro-
spheres 
liver 
metastases 
from breast 
cancer 
n=17 pro-
spective 
yes 6 weeks - - no no TLG 
(>50% 
decrea
se) 
overall survival follow-
up 
Yes 
Barabasch et 
al. Invest 
Radiol 2015 
Y-90 
microspheres 
liver 
metastases 
from 
different 
primary 
tumors 
n=35 pro-
spective 
yes 6 weeks 
(n=31) 
- - - MRI 
(ADCmin) 
SUVm
ax 
(>30% 
decrea
se) 
tumor 
response 
follow-
up, MRI 
Yes 
Kucuk et al. 
Worl J Surg 
Y-90 micro-
spheres 
liver 
metastases 
n=78 retro-
spective 
yes 6 weeks 12 
week
18 weeks yes no SUVm
ax 
treatment 
response 
follow-
up 
yes 
Oncol 2011 from 
different 
primary 
tumors 
s (>20% 
decrea
se) 
Willowson et 
al. EJNMMI 
res 2017 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=22 retrospecti
ve 
yes <8 weeks - - - no delta-
TLG 
(50% 
decrea
se) 
SUVpe
ak 
overall survival follow-
up 
Yes 
Edalat et al. 
Clin Nucl 
Med 2016 
Y-90 micro-
spheres 
liver 
metastases 
colorectal 
cancer 
n=16 retro-
spective 
yes 0.9-5.7 
months 
n/a n/a n/a ceCT 
and/or MR 
PERCI
ST, 
TLG, 
SUVpe
ak, 
SAM 
overall survival follow-
up 
No 
Shady et al. 
Eur J Rad 
2016 
Y-90 
microspheres 
liver 
metastases 
from 
colorectal 
cancer 
n=49 retro-
spective 
yes 3-11 
weeks 
(median 
6 weeks) 
    SUVm
ax, 
SUVpe
ak, 
MTP 
and 
TLG 
overall survival follow-
up 
yes 
Shady et al. 
AJR 2016 
Y-90 
microspheres 
liver 
metastases 
from 
colorectal 
cancer 
n=25 retro-
spective 
yes 4-8 
weeks 
every 
2 
mont
hs 
until 
progr
essio
n 
  ceCT 
(RECIST, 
Choi) 
EORT
C 
criteria 
liver 
progression 
free survival 
follow-
up 
yes 
indication: radioembolisation for cholangiocellular carcinoma  
Haug et al. 
Eur J Nucl 
Med Mol 
Imaging 2011 
Y-90 micro-
spheres 
intrahepatic 
cholangio-
cellular 
carcinoma 
n=26 pro-
spective 
Yes 3 months -  -  -  no delta-
SUVm
ax, 
delta-
overall survival follow-
up  
Yes 
SUVm
ean, 
deltaM
TV 
Filippi et al. 
Nucl Med 
Biol 2015 
Y-90 micro-
spheres 
intrahepatic 
cholangio-
cellular 
carcinoma 
n=17 pro-
spective 
Yes 6 weeks 3 
mont
hs 
6 months 9  months no detla-
TLG 
(PERC
IST) 
 follow-
up 
Yes 
 
  
 TABLE 4. Main results of studies with imaging at early and late time points to evaluate treatment efficacy  
Author local therapy tumor type nr of 
pts 
Main results/ conclusion QUADAS 
criteria met 
indication: RFA and cryoablation in liver metastases   
Joosten et al. 
Eur J Surg 
Oncol 2005 
RFA and cryo-
ablation w/ or 
w/o resection 
liver 
metastases 
from 
colorectal 
cancer 
n=43  In a subgroup analysis on 43 patients with 104 ablated lesions, CT scan immediate after treatment 
was not able to predict local treatment failure, whereas FDG-PET scan within 3 weeks after local 
ablative treatment predicted 6/7 local recurrences. 
yes 
Langenhoff 
et al. J Clin 
Oncol 2002 
RFA and cryo-
ablation w/ or 
w/o resection 
liver 
metastases 
from 
colorectal 
cancer 
n=23 51 lesions became photopenic on FDG-PET, while 5 lesions showed persistent activity on FDG-
PET. In 4/5 FDG-PET-positive lesions, a local recurrence developed during follow-up; one FDG-
PET-positive lesion turned out to be an abscess. None of the FDG-PET-negative lesions 
developed a local recurrence during follow-up. 
FDG-PET showed all 9 cases with extra-hepatic recurrence. 
Detection of recurrence by FDG-PET was considerably earlier than the detection by CT. 
yes 
Donckier et 
al. J Surg 
Oncol 2003 
RFA liver 
metastases 
 
n=17 In four patients, FDG-PET at 1 week and 1 month showed peripheral hypermetabolic residue after 
RFA, whereas CT did not revealed residual tumor. In three patients, local persistence of viable 
tumor cells was biopsy-proven at reintervention. In the fourth, follow-up CT showed subsequent 
development of a local recurrence. 
FDG-PET accurately monitors the local efficacy of RFA for treatment of liver metastases, as it 
early recognizes incomplete tumor ablation, not detectable on CT 
yes 
Chen et al. 
Ann Nucl 
Med 2013 
RFA primary 
liver tumor 
or 
metastases 
n=28 PET identified 16 out of 17 recurrent/residual tumors with a sensitivity of 94.1 %, specificity 81.3%. 
Sensitivity of CT and MRI 66.7%, specificity 62,5 and 87,5% respectively. 
The study suggests that FDG-PET is superior to MRI and/or CT and is more cost-effective in post 
RFA hepatic tumor assessment. 
yes 
Nielsen et al 
Eur J Radiol 
2013 
RFA liver 
metastases 
from 
colorectal 
cancer 
n=79 Regular follow-up using FDG PET-CT within this period is advised, so repeated treatment can be 
initiated. Rim-shaped uptake may be present until 4-6 months, complicating evaluation. The 
benefit in the follow-up of lesions <2 cm may be limited. 
no 
Sahin et al. 
Ann Surg 
Oncol 2012 
RFA liver 
metastases 
from 
colorectal 
cancer 
n=104 PET/CT findings were equivalent to ce CT in 55 patients (67%), superior in 22 (27%), and inferior 
in 5 (6%). Pre-RFA or post-RFA PET imaging did not affect overall survival. 
PET/CT was superior to ce CT in demonstrating recurrence after RFA in about a quarter of the 
patients with CLM. 
no 
indication: RFA and cryoablation for lung lesions  
Yoo et al. Am 
J Roentgenol 
2011 
RFA irresectable 
primary 
non-small 
cell lung 
cancer 
n=30 Patients with a complete metabolic response at early PET/CT had a 1-year event rate of 43%, 
whereas those with partial or no response or disease progression had a 1-year event rate of 67% 
(p = 0.27). Patients with a complete metabolic response at 6-month PET/CT had a 1-year event 
rate of 0%. Those with a partial response and those with disease progression had an overall event 
rate of 75% (p = 0.001) 
Early post-RFA PET/CT is not necessary and 6-month post-RFA PET/CT findings correlate better 
with clinical outcome at 1 year. 
yes 
Lafuente et 
al. Rev Esp 
Med Nucl 
Imagen Mol 
2016 
RFA lung 
metastases 
colorectal 
cancer 
n=18 The retention index (dual time point PET) at 1 month after RFA showed a sensitivity and specificity 
of 83% and 92%, respectively. 
Dual time point PET/CT can predict the outcome at one month after RFA in lung metastases from 
digestive tract cancers. The retention index can be used to indicate the need for further 
procedures to rule out persistent tumor due to incomplete RFA. 
no 
Deandreis et 
al. Radiology 
2011 
RFA lung 
carcinoma 
or lung 
metastases 
n=34 Within 3 months after RF ablation, incomplete treatment was diagnosed in four of 28 patients 
(14%, three at 1 month and one at 3 months). Findings of FDG PET/CT were true positive in four, 
false positive in one, and true negative in 23 patients. Findings of chest CT were true positive in 
one, false positive in one, false negative in three, and true negative in 23 patients. 
yes 
Higuchi et al. 
J Cancer Res 
Clin Oncol 
2014 
RFA lung 
carcinoma 
or lung 
metastases 
n=20 The FDG-PET results 7-14 days after RFA did not predict recurrence, whereas positive findings 3-
6 months after RFA significantly correlated with local recurrence (p = 0.0016) 
We confirmed the effectiveness of RFA for unresectable primary and secondary thoracic 
malignancies. FDG-PET analysis 3-6 months after ablation is a useful tool to assess local control. 
yes 
Higaki et al. 
Ann Nucl 
Med 2008 
RFA lung 
carcinoma 
or lung 
metastases 
n=15 Of 60 tumors, 10 showed local progression. The area under the ROC curve (AUC) for the 6-9 
months (P = 0.044) was the largest and almost equal to that of the 3-6 months (P = 0.024). AUC 
for the 0-3 months was the smallest and statistically insignificant (P = 0.705). The cutoff value of 
1.5 of SUVmax at 3-9 months after RFA showed 77.8% sensitivity and 85.7-90.5% specificity. 
The appropriate follow-up initiation time point is at least 3 months following RFA. 
yes 
Alafate et al. 
Acta Med 
Okayama 
2013 
RFA lung cancer 
or lung 
metastases 
n=25 SUVmax was more reliable than the size measurements by CT in the first 6 months after RFA, and 
PET/CT at 6 months post-RFA may be more appropriate for the assessment of FDG accumulation 
than that at 3 months post-RFA. 
no 
Wang et al. 
Int J Clin Exp 
Med 2015 
RFA lung 
metastases 
from - lung 
carcinoma 
n=58 Increased metabolic activity, new uptake of FDG, and irregular or nodular high uptake of FDG 
(maximum standard uptake value (SUVmax) ≥3) of the ablated zone after 3 months were all 
findings concerning recurrence or residual. 
yes 
Bonichon et 
al. Eur J Nucl 
RFA lung 
metastases 
n=89 PET/CT at 3 months and the reference standard were available in 77 patients and 100 lesions. 
Accuracy was 66.00% (95% CI 55.85-75.18%), sensitivity 90.91% (95 % CI 58.72-99.77 %), 
yes 
Med Mol 
Imaging 2013 
specificity 62.92% (95% CI 52.03-72.93%), PPV 23.26% (95% CI 11.76-38.63%), and NPV 
98.25% (95% CI 90.61-99.96%). 
The specificity of PET/CT at 3 months is low. It is useful for its negative predictive value, but 
positive findings need to be confirmed. 
Singnurkar et 
al. J Nucl 
Med 2010 
RFA lung 
carcinoma 
or lung 
metastases 
n=68 
(56 
adequ
ate 
imagin
g) 
Post-RFA factors that related to reduced recurrence-free survival included an unfavorable uptake 
pattern (P < 0.01), post-RFA SUV (P < 0.01), and an increase in SUV over time after ablation (P = 
0.05). 
no 
Suzawa et al. 
Clin Nucl 
Med 2013 
RFA lung 
carcinoma 
or lung 
metastases 
n=143 The area under the ROC curve of PET was higher than that of CT at all 4 time points (0.71 vs 0.55 
at 3 months, 0.82 vs 0.60 at 6 months, 0.84 vs 0.66 at 9 months, and 0.92 vs 0.68 at 12 months), 
and its diagnostic performance was significant at each time point (P = 0.0010 at 3 months and P < 
0.001 at 6, 9, and 12 months). 
FDG PET/CT is better able to assess local tumor progression at 3 and 6 months after lung RFA 
than CT alone. 
yes 
LoGiurato et 
al. Nucl Med 
Commun 
2015 
cryoablation non-small 
cell lung 
cancer 
n=28 FDG PET-CT is a valuable tool for determining treatment response and for distinguishing benign 
from malignant lesions after cryoablation. The CT area was most predictive of future recurrence at 
baseline, whereas SUVmax more than or equal to 2.5 was most predictive of future recurrence at 
first follow-up. 
yes 
indication: regional ablative therapy in hepatocellular carcinoma  
Higashi et al. 
Eur J Nucl 
Med Mol 
Imaging 2010 
TACE, TAC, 
RFA or systemic 
chemo-therapy 
hepato-
cellular 
carcinoma 
n=60  Visual PET diagnosis of post-therapeutic lesions was a good predictor of overall survival of 
unresectable HCC patients. The low FDG group showed significantly longer survival (average: 608 
days) than that (average: 328 days) of the high FDG group (p < 0.0001). 
no 
Sabet et al. 
Nuklearmedi
zin 2014 
Y-90 
microspheres 
hepato-
cellular 
carcinoma 
n=33 FDG-negative patients had a significantly longer OS (13 months, 95%CI 7-19) than FDG-positive 
patients (9 months, 95%CI 7-11; p = 0.010). Among FDG-positive patients, metabolic responders 
survived significantly longer than metabolic non-responders (10 months, 95%CI 8-12 vs. 5 months, 
95%CI 4-6; p = 0.003). 
Pre- and post-therapeutic FDG PET independently predicts overall survival in patients with HCC 
undergoing radioembolization.  
yes 
Ma et al. 
Theranostics 
2014 
TACE hepato-
cellular 
carcinoma 
n=27 The ΔTSUVmax%, based on the VOI, had the highest discriminative prognostic value.The OS was 
significantly better in the PET/CT response group than in the PET/CT non-response group 
(p=0.025). 
yes 
Kim et al. 
Nucl Med 
RFA, TACE or 
ethanol injection 
hepato-
cellular 
n=31 By visual analysis, the respective values for sensitivity, specificity, positive predictive value, 
negative predictive value, and accuracy were 87.5, 71.4, 77.8, 83.3, and 80.0 %. However, there 
no 
Mol Imaging 
2012 
carcinoma were no significant differences in the SUVmax and TNR between the two groups. 
Paudyal et al. 
Oncol Rep 
2007 
RFA hepato-
cellular 
carcinoma 
n=24 FDG PET detected recurrence earlier than CT between 4-6 months in 2 patients and between 7-9 
months in 6 patients whereas CT was positive in 4 patients. Overall detection rate of recurrence 
with FDG PET was 92% which was higher than that of CT (75%). 
yes 
Li et al. Eur J 
Nucl Med 
Mol Imaging 
2017 
TACE (+/-
bevacizumab) 
hepato-
cellular 
carcinoma 
n=22 In patients treated with TACE and placebo, there was a significant difference in mean OS in 
patients with positive FDG PET as compared with that in patients with negative FDG PET (p = 
0.048). Although the OS days in patients with positive acetate PET were shorter as compared with 
those in patients with negative acetate PET, there was no statistically significant difference (p = 
0.063). 
yes 
Cascales-
Campo et al. 
Transplant 
Proc 2015 
TACE hepato-
cellular 
carcinoma 
undergoing 
orthotopic 
liver 
transplantat
ion 
n=20 Among patients whose post-TACE SUV decreased to <3, >70% necrosis was observed upon 
study of a hepatectomy sample, with a survival rate of 100% and 80% at 1 and 3 years, 
respectively. 
no 
Song et al. 
Clin Radiol 
2015 
TACE hepato-
cellular 
carcinoma 
n=73 Comparing the receiver-operating characteristic area, (18)F-FDG-PET/CT was found to be 
superior to CECT for the detection of viable tumour in patients with HCC after TACE (p = 0.04). 
The overall survival rate was significantly higher in the low SUV ratio (TSUVmax/LSUVmean<1.65) 
group (p = 0.024). 
no 
Wang et al. J 
Dig Dis 2013 
status after 
surgery and/or 
RFA 
recurrence 
of hepato-
cellular 
carcinoma 
n=36 The sensitivity, specificity of (18) F-FDG-PET/CT for intrahepatic HCC recurrence were 96.7% and 
83.3%, respectively. The corresponding values of CEUS were 56.7% and 100%, respectively. The 
sensitivity and accuracy of (18) F-FDG-PET/CT for the diagnosis of HCC recurrence were 
significantly higher than those of CEUS (P<0.01). 
yes 
indication: radioembolisation in liver metastases  
Miller et al. 
Am J 
Roentgenol 
2007 
Y-90 micro-
spheres 
liver 
metastases 
from 
different 
primary 
tumors 
n=23  PET detected significantly more responses to treatment (21/33, 63%) than CT using RECIST 
(2/33, 6%) or combined criteria (8/33, 24%) (p < 0.05, McNemar test). 
The use of necrosis and size criteria on CT and corrlation with PET may improve the accuracy of 
assessment of response to 90Y treatment in patients with liver metastases and detect response 
earlier than standard size criteria. 
yes 
Gulec et al. 
Eur J Nucl 
Med Mol 
Y-90 resin 
microspheres 
liver 
metastases 
from 
n=20 Pretreatment and posttreatment FTV and TLG showed very strong association with survival. 
These values can be useful quantitative criteria for patient selection and disease prognostication 
when (90)Y SIRT is contemplated in patients with CRCLM. 
yes 
Imaging 2011 colorectal 
cancer 
Sabet et al. 
Eur J Nucl 
Med Mol 
Imaging 2015 
Y-90 micro-
spheres 
liver 
dominant 
metastatic 
colorectal 
cancer 
n=51 The median OS after RE was 7 months [95 % confidence interval (CI) 5-8]; early metabolic 
responders (n=33) survived longer than non-responders (p<0.001) with a median OS of 
10 months (95 % CI 3-16) versus 4 months (95 % CI 2-6). 
Molecular response assessment in CRC using (18)F-FDG PET/CT appears feasible as early as 
4 weeks post-RE. 
yes 
Kalva et al. 
Am J Clin 
Oncol 2017 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=45 Per RECIST, 1 patient (2%) had partial response, 34 (71%) had stable disease, and 6 (13%) had 
progressive disease. PET response was seen in 46% of patients with 2 patients (4%) 
demonstrating complete and 22 (42%) demonstrating partial metabolic response. The median 
survival was 186 days (95% CI, 149-277 d). Response on PET was the only independent predictor 
of superior overall survival. 
no 
Fendler et al. 
J Nucl Med 
2013 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=80 Responders who had a change in metabolic volume or total lesion glycolysis had significantly 
longer survival (92 vs. 49 wk [P = 0.006] and 91 vs. 48 wk [P = 0.025], respectively). However, 
neither RECIST 1.1 criteria nor changes in SUV(peak) or SUV(max) after treatment predicted 
outcome (P = 0.086 for RECIST; P = 0.310 for change in SUV(peak); P = 0.155 for change in 
SUV(max)). 
yes 
Fendler et al. 
J Nucl Med 
2016 
Y-90 micro-
spheres 
liver 
metastases 
from breast 
cancer 
n=81 Twenty-nine of 56 (52%) patients responded to radioembolization based on FDG PET criteria. yes 
Haug et al. J 
Nucl Med 
2012 
Y-90 micro-
spheres 
liver 
metastases 
from breast 
cancer 
n=58 Response as assessed with SUV(max) correlated significantly with survival after 
radioembolization, with responders having significantly longer survival (65 wk) than nonresponders 
(43 wk; P < 0.05’ 
The change in SUV(max) as assessed by (18)F-FDG PET/CT before and 3 mo after SIRT was 
identified as the only independent predictor of survival in patients with hepatic metastases of 
breast cancer. 
no 
Michl et al. J 
Nucl Med 
2016 
Y-90 micro-
spheres 
liver 
metastases 
from 
pancreatic 
cancer 
n=17 Metabolic response by change in SUVpeak (7/17) and change in total-lesion glycolysis (7/17) was 
a predictor for overall survival (P = 0.039; hazard ratio [HR], 0.24; 95% confidence interval [CI], 
0.06-0.93), progression-free survival (P = 0.016; HR, 0.15; 95% CI, 0.03-0.69), and time to 
intrahepatic progression (P = 0.010; HR, 0.16; 95% CI, 0.04-0.65). Summed CT diameter did not 
predict overall or progression free survival. 
yes 
Sofocleous et 
al. Clin 
Colorectal 
Cancer 2014 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=19 Responses by RECIST, PERCIST, and CEA were, respectively, 0%, 20%, and 32% at 4 to 8 
weeks and 5%, 33%, and 21% at 3 to 4 months post SIRT; 53% of patients had stable disease (by 
RECIST) at 3 to 4 months. 
yes 
Sofocleous et 
al. Clin 
Colorectal 
Cancer 2015 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=53 Evaluation using PERCIST was more likely than RECIST to document response or progression 
compared with the baseline assessment before RE. 
no 
Szyszko et 
al. Nucl Med 
Commun 
2007 
Y-90 micro-
spheres 
liver 
metastases 
different 
primary 
tumors 
n=21 FDG PET imaging is more sensitive than CT in the assessment of early response to SIR spheres, 
allowing clinicians to proceed with further therapeutic options. 
yes 
Zerizer et al. 
Eur J Nucl 
Med Mol 
Imaging 2012 
Y-90 micro-
spheres 
liver 
metastases 
from 
colorectal 
cancer 
n=25 The responses on the FDG PET/CT studies were highly correlated with the responses of tumor 
markers. The responses on (18)F-FDG PET/CT studies also significantly predicted PFS, while 
RECIST and tumor density did not. 
yes 
Bagni et al. 
Cancer 
Biother 
Radiopharm 
2015 
Y-90 micro-
spheres 
liver 
metastases 
from breast 
cancer 
n=17 Subjects with a ΔTLG >50% and ΔTLG <50% had a mean OS of 16.4±0.6 and 10.3±0.4 
months, respectively (p<0.001). Cox regression analysis demonstrated hepatic tumor load 
(p=0.048) and ΔTLG as the only significant (p=0.005) predictors of survival. 
yes 
Barabasch et 
al. Invest 
Radiol 2015 
Y-90 micro-
spheres 
liver 
metastases 
from 
different 
primary 
tumors 
n=35 Diffusion-weighted magnetic resonance imaging appears superior to PET/CT for early response 
assessment in patients with hepatic metastases of common solid tumors. 
yes 
Kucuk et al. 
Worl J Surg 
Oncol 2011 
Y-90 micro-
spheres 
liver 
metastases 
from 
different 
primary 
tumors 
n=78 In the evaluation of treatment response; 43(55%) patients were responder (R) and 35 (45%) 
patients were non-responder (NR) in the sixth week F18-FDG PET/CT. 
FDG PET/CT is seen to be a successful imaging method in evaluating treatment response for 
predicting survival times in this patient group. 
yes 
Willowson et 
al. EJNMMI 
res 2017 
Y-90 micro-
spheres 
Liver 
metastases 
from 
colorectal 
cancer 
n=22 Early reduction in TLG at follow-up may be prognostic for overall survival. yes 
Edalat et al. 
Clin Nucl 
Med 2016 
Y-90 micro-
spheres 
liver 
metastases 
colorectal 
cancer 
n=16 After Y-90 microspheres, ΔSAM showed an objective response rate of 40%.  Median overall 
survival (OS) of the cohort after Y was 9.2 months (CI 95% 2.2-16.2). Patients demonstrating 
objective response based on ΔSAM had a median OS of 22.7 months (CI 95% 12.4-33.0) vs. 6.7 
(CI 95% 4.2-9.2) in non-responders (P = 0.007). 
no 
Shady et al. 
Eur J Rad 
2016 
Y-90 micro-
spheres 
Liver 
metastases 
from 
colorectal 
cancer 
n=49 Metabolic response based on changes in MTV and TLG can predict OS post-radioembolisation of 
colorectal liver metastases. 
yes 
Shady et al. 
AJR  2016 
Y-90 micro-
spheres 
Liver 
metastases 
from 
colorectal 
cancer 
n=25 EORTC PET criteria, Choi criteria, and tumor attenuation criteria appear to be equally reliable 
surrogate imaging biomarkers of liver PFS after radioembolisation in patients with liver metastases 
from colorectal cancer. 
yes 
indication: radioembolisation in cholangiocellular carcinoma  
Haug et al. 
Eur J Nucl 
Med Mol 
Imaging 2011 
Y-90 micro-
spheres 
intrahepatic 
cholangio-
cellular 
carcinoma 
n=26 The change in all FDG values significantly predicted survival by Kaplan-Meier analysis after 
radioembolisation. 
yes 
Filippi et al. 
Nucl Med 
Biol 2015 
Y-90 micro-
sheres 
intrahepatic 
cholangio-
cellular 
carcinoma 
n=17 A decrease in total lesion glycolysis (TLG) of >50% within 6 weeks after treatment is significantly 
associated with both longer time-to-progression (36.9 versus 13.7 weeks) as well as improved 
overall survival (79.6 versus 43.1 weeks) 
yes 
 
  
  
TABLE 7. Evaluation of included studies according to QUADAS criteria 
 
 
Risk of bias Applicability concerns  
Patient selection Index test Reference 
standard 
Flow and timing Patient 
selection 
Index test Reference 
standard 
criteria 
met 
studies with imaging <48 hours to evaluate technical treatment success  
Cornelis et al. J 
Nucl Med 2016 
    <25 patients, 
different 
primary tumors 
  yes 
VandenBrouck
e et al. J Vasc 
Interv Radiol 
2014 
   Short follow-up (8-10 
weeks) 
<25 patients   yes 
Kuehl et al. Clin 
Oncol 2008 
   Not all patients 
received a PET-CT 
shortly after treatment 
   yes 
Kuehl et al. Eur 
J Radiol 2008 
    <25 patients   yes 
Ryan et al. 
Radiology 2013 
   
 
<25 patients, 
different 
primary tumors 
  yes 
indication: RFA and cryoablation in liver metastases  
Joosten et al. 
Eur J Surg 
Oncol 2005 
43/58 of patients 
had a PET 
      yes 
Langenhoff et 
al. J Clin Oncol 
2002 
    <25 patients   yes 
Donckier et al. 
J Surg Oncol 
2003 
    <25 patients   yes 
Chen et al. Ann 
Nucl Med 2013  
   Wide range of imaging 
time points (<8 weeks) 
   yes 
Nielsen et al. 
Eur J Radiol 
2013 
  Follow-up not 
specified 
Wide range of imaging 
time points 
   no 
Sahin et al.     compares   no 
Ann Surg 
Oncol 2012 
survival with 
and without 
PET 
indication: RFA for lung lesions  
Yoo et al. Am J 
Roentgenol 
2011 
   Long interval (6 
months) after 
intervention  
   yes 
LaFuente et al. 
Rev Esp Med 
Nucl Imagen 
Mol 2016 
  Unclear how 
local 
recurrence 
was objected 
 <25 patients   no 
Deandreis et al. 
Radiology 2011 
       yes 
Higuchi et al. J 
Cancer Res 
Clin Oncol 
2014 
    <25 patients   yes 
Higaki et al. 
Ann Nucl Med 
2008 
   Wide range of imaging 
time points (1-3 
months, 3-6 months 
and 6-9 months) 
<25 patients   yes 
Alafate et al. 
Acta Med 
Okayama 2013 
    <25 patients, 
exclusion of 
patients with 
local 
recurrence or 
adjuvant 
chemotherapy 
  no 
Wang et al. Int 
J Clin Exp Med 
2015 
       yes 
Bonichon et al. 
Eur J Nucl Med 
Mol Imaging 
2013 
       yes 
Singnurkar et 
al. J Nucl Med 
2010 
12/68 patients 
inadequate 
follow-up 
  Wide range of imaging 
time points (1-4 
months) 
   no 
 Suzawa et al. 
Clin Nucl Med 
2013 
 Unclear if reviewers were 
blinded for outcome 
     yes 
LoGiurato et al. 
2015 
 Cut-off value was not 
predefined 
     yes 
indication: regional ablative therapy in hepatocellular carcinoma  
Higashi et al. 
Eur J Nucl Med 
Mol Imaging 
2010 
    Various 
interventions 
and some 
patients 
received 
systemic 
treatment 
  no 
Sabet et al. 
Nuklearmedizin 
2014 
        
Ma et al. 2014  Many parameters tested 
in a small sample size 
     yes 
Kim et al. Nucl 
Med Mol 
Imaging 2012 
   Short follow-up (6 
months) 
Small 
population with 
various 
interventions 
  no 
Paudyal et al. 
Oncol Rep 
2007 
    <25 patients   yes 
Li et al. Eur J 
Nucl Med Mol 
Imaging 2017 
    <25 patients   yes 
Cascales-
Campos et al. 
Transplant 
Proc 2015 
   Time point after 
intervention not 
specified. <8 weeks 
before liver 
transplantation 
<25 patients   no 
Song et al. Clin 
Radiol 2015 
 Cut-off value was not 
predefined 
 Wide range of imaging 
time points  
   no 
Wang et al. J 
Dig Dis 2013 
    Follow-up with 
PET on 
  yes 
indication 
indication: radioembolisation in liver metastases  
Miller et al. 
2007 
   Short follow-up (mean 
101 days) 
   yes 
Gulec et al. Eur 
J Nucl Med Mol 
Imaging 2011 
    <25 patients, 
Response 
evaluation not 
primary 
research goal 
  yes 
Sabet et al. Eur 
J Nucl Med Mol 
Imaging 2015 
       yes 
Kalva et al. Am 
J Clin 
 Cut-off value was not 
predefined 
  Response 
evaluation not 
primary 
research goal 
  no 
Fendler et al. J 
Nucl Med 2013 
       yes 
Fendler et al. J 
Nucl Med 2016 
       yes 
Michl et al. J 
Nucl Med 2016 
    <25 patients    
Haug et al. J 
Nucl Med 2012 
43/58 of patients 
had a PET-CT 
  Long (3 months) 
interval between 
intervention and 
imaging  
   no 
Sofocleous et 
al. Clin 
colorectal 
cancer 2014 
Small group of 
patients, divided 
in 3 cohorts 
   <25 patients   yes 
Sofocleous et 
al. Clin 
colorectal 
cancer 2015 
   64% had additional 
therapies during 
follow-up/response 
evaluation 
   no 
Szysko et al. 
Nuc Med 
Comm 2007 
   Only 14/21 patients 
had a PET-CT after 6 
weeks 
<25 patients   yes 
Zerizer et al.        yes 
Eur J Nucl Med 
Mol Imaging 
2012 
Bagni et al. 
Cancer Biother 
Radiopharm 
2015 
   Range of imaging time 
points < 6 weeks 
<25 patients   yes 
Barabasch et 
al. Invest 
Radiol 2015 
       yes 
Kucuk et al. 
World J Surg 
Oncol 2011 
   Different primary 
tumors 
   yes 
Willowson et al. 
EJNMMI res 
2017 
    <25 patients   yes 
Edalat et al. 
Clin Nucl Med 
2016 
   Interval between 
intervention and PET 
not specified 
<25 patients   no 
Shady et al. 
AJR 2016 
   
 
<25 patients, 
different 
primary tumors 
  yes 
Shady et al. 
Eur J Rad 2016 
   Wide range of imaging 
time point (between 3-
11 weeks) 
   yes 
indication: radioembolisation in cholangiocellular carcinoma  
Haug et al. Eur 
J Nucl Med Mol 
Imaging 2011 
       yes 
Filippi et al. 
Nuc Med Biol 
2015 
    <25 patients   yes 
 
 
